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INDUCTION OF APOPTOSIS BY RUBELLA VIRUS 
 NON-STRUCTURAL REPLICASE AND RESCUE BY CAPSID 
 
by 
 
ALISON KANAK 
 
Under the Direction of Dr Teryl Frey 
 
ABSTRACT 
 
As a model for studying apoptosis associated with pathogenesis of congenital rubella 
syndrome, bicistronic rubella virus (RUBV) replicons expressing an antibiotic resistance gene in 
the presence (925-IN) or absence (IN-IN) of RUBV capsid protein (C) were constructed. 
Apoptosis was assessed by detection of caspase activation, chromatin fragmentation, and flow 
cytometry. 925-IN cells grew similarly to Vero, but  IN-IN cells demonstrated caspase 
activation, chromatin fragmentation and cell cycle arrest. Whereas Vero cells transfected with 
P150 exhibited rapid apoptosis not detected in transfected Vero cells stably expressing C, neither 
exhibited cell cycle alterations, indicating a cell cycle stall not associated with apoptosis. Finally, 
two human epithelial cells, HEK293 and A549, transfected with P150 failed to exhibit apoptosis, 
indicating that while replicon-transfected Vero cells are useful for studying apoptosis and cell 
cycle arrest, the results are not applicable to other cell types. 
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 CHAPTER I 
INTRODUCTION 
OVERVIEW 
 
 Since its first description in the mid-eighteenth century by Friederich Hoffmann, and 
subsequent descriptions by de Bergen and Orlow, [1] rubella has consistently been 
misunderstood.  Initially believed to be a manifestation of scarlet fever or measles, it was not 
until almost one hundred years later that rubella was classified as a disease of its own [2]. It then 
required another hundred years for the causative agent of rubella, the rubella virus (RUBV), to 
be isolated in 1962 despite the fact that related members of the Togaviridae family, to which 
RUBV belongs, had been isolated years before [3]. Even though it has been almost 50 years 
since its isolation, knowledge of its molecular workings remains incomplete. Of course, since 
successful vaccination efforts have eliminated rubella from the majority of developed countries 
in the world [4], the question may be posed as to why this virus is even worth continued study. 
The answer to this question was addressed by ophthalmologist Norman Gregg in 1941 [10]. Dr. 
Gregg, after noticing a substantial number of congenital cataracts in babies born from mothers 
infected with rubella during pregnancy, described a wide variety of birth defects that we now 
know as Congenital Rubella Syndrome, or CRS. He went on to correlate the severity of the birth 
defects with how early in her pregnancy the mother was infected [5]. Given that CRS still exists 
today in most underdeveloped countries and that other infectious agents also cause birth defects, 
it is vital to understand the process by which infectious disease can interrupt development of 
fetal systems. Thus the goal of this research is to take steps towards understanding the molecular 
mechanisms of CRS with the hypothesis that it is the induction of apoptosis by RUBV that 
causes at least some of the birth defects associated with CRS. 
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 RUBELLA, THE DISEASE 
History 
 Rubella got its initial recognition in human history by being confused with measles and 
scarlet fever, due to the similarities in appearance of the rashes that these diseases produce. In 
fact, Friederich Hoffmann reported the first clinical description of rubella in 1740 without 
classifying it as a separate disease entity [6]. This description was later confirmed by Drs de 
Bergen and Orlow in 1752 and 1758, respectively [1]. It wasn’t until 1814 that George de Maton 
proposed for the first time that rubella be classified as a disease distinct from both measles and 
scarlet fever [7]. The fact that all of these men were of German descent is why rubella came to be 
known as “German Measles”. Rubella was given its official name by an English Artillery 
Surgeon in India, Henry Veale, in 1866. He decided on this name because in Latin rubella means 
“little red”, thus correlating to the red rash that rubella produces [6]. Finally, 1881 saw the 
official recognition of rubella as a distinct disease at the International Congress of Medicine in 
London [2]. This official classification led to the beginnings of research on rubella. The early 
1900’s saw the beginnings of the idea that rubella was caused by a virus based on Alfred Hess’ 
work with monkeys [8]. Hiro and Tosaka confirmed this hypothesis in 1938 by passing the 
disease to healthy children with filtered nasal washings of acutely infected individuals [5].  
The cornerstone for rubella as a disease of significance, rather than a benign illness, was 
the discovery of its role in causing congenital birth defects. After a widespread epidemic of 
rubella in Australia in 1940, Norman Gregg noticed a strong correlation between children born 
with congenital cataracts and children born to women infected with rubella early in their 
pregnancy [9]. These observations led Gregg to publish his paper, Congenital Cataracts 
Following German Measles in the Mother in 1941, in which he described a number of congenital 
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 defects that are today grouped together and classified as Congenital Rubella Syndrome (or CRS). 
In this paper, he also noted the positive correlation between the severity of the syndrome and the 
trimester during which the mother was infected, a correlation that has been confirmed [10]. The 
true impact of CRS was brought home in the rubella epidemic of 1964-1965, when 20,000 CRS 
cases occurred in the US and 1% of births in New York alone were diagnosed with CRS. 
Finally, in 1962 the RUBV was isolated and identified simultaneously by two 
independent groups [11, 12]. Later in the same decade, live attenuated vaccines against this virus 
were generated and implemented in vaccination programs, first on its own and then ten years 
later as part of the triple vaccine against measles, mumps and rubella (MMR). Since the licensing 
of the rubella vaccine, the occurrence of rubella has gone from 12.5 million cases annually to 
nearly  complete elimination in North America [5]. 
 
The Disease 
Infection with RUBV results in a typically mild disease called rubella,  German Measles, 
or three-day measles [13]. Due to vaccination efforts in the U.S., the incidence of rubella has 
declined precipitously and has changed from a predominantly childhood disease to one that 
mostly affects unimmunized young adults, usually of foreign origin [4].  
Symptoms of rubella begin with a mild fever and swollen lymph nodes around the throat. 
Following this stage is the appearance of a rash resulting from the inflammatory response of the 
immune system with small pink or red spots on the face and chest that gradually spreads 
outward.  At the time of appearance of the rash, antibodies against the virus become detectable 
and the infection is resolved.  Many people infected with rubella have either very mild symptoms 
or none at all, but infection can also result in arthritis in adult women and congenital birth defects 
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 in the fetus if the woman infected is pregnant [3].  Rarer sequelae include encephalitis and 
thrombocytopenia purpura. 
The pathogenesis of RUBV infection is poorly understood because of the benign nature 
of the disease, because humans are the only known host and there is no animal model.  The 
following are general steps in the infection cycle: RUBV replicates in the nasopharynx, both 
initially and following systemic infection, and is thus spread from person-to-person through 
direct droplet contact with the respiratory secretions of infected individuals. Upon entry into the 
respiratory tract, the virus infects cells of the respiratory epithelium and spreads to local lymph 
nodes, resulting in a primary non-cellular associated viremia that culminates in dissemination of 
the virus through the blood stream. Following this viremia, the virus is seeded in its target 
organs, such as the spleen and distant lymph nodes, where it undergoes a second round of 
replication [4]. At this point, approximately seven days after infection and about ten days before 
the onset of an immunopathologic rash, the virus can be recovered from the blood serum [9]. The 
maculopapular rash appears roughly three weeks after infection and appearance of the rash 
coincides with virus shedding from the nasopharynx.  Shortly after the onset of the rash, viremia 
ceases and transformed lymphocytes as well as neutralizing antibodies can be detected in the 
blood. The virus continues to be shed from the respiratory tract, however, usually for less than a 
week, but occasionally for up to twenty eight days following the appearance of the rash [14]. 
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 Congenital Rubella Syndrome 
While infection with RUBV only causes mild disease when contracted post-natally, it can 
cause severe birth defects (CRS) in a fetus, especially if infection is during the first trimester of 
pregnancy. Abnormalities induced can include deafness, blindness, mental retardation, and 
congenital heart defects [15]. In addition to these symptoms apparent at birth, individuals 
diagnosed with CRS and followed for 50 years also had a predisposition towards late-onset 
illnesses such as insulin-dependent diabetes, thyroid dysfunction, and panencephalitis [16]. 
 It is believed that it is during the period of viremia in the mother that the virus infects 
and then crosses the placenta to infect the fetus. The exact mechanisms of how the virus crosses 
the placenta have not been elucidated. Since the fetus has not yet developed its immune system, 
it must rely on antibodies secreted by the mother who is in the process of producing antibodies of 
her own against the virus. Thus, the titer of maternal antibodies is too low and transfer of these 
antibodies is too inefficient due to the predominant production of antibodies being IgM, which 
cannot cross the placenta, to be able to effectively combat the virus that is now in the fetus’ 
system. Since the fetus has no adaptive defense system against the virus at this time in 
development, RUBV can infect and damage any organ system as well as maintain a chronic 
nonlytic infection in the fetal cells. In fact, following infection early in pregnancy, the virus 
persists and can be recovered for up to a year after birth [3].  This persistence is in spite of the 
eventual induction of neutralizing antibodies in the fetus as well as the fact that immunological 
tolerance never develops [17].  It is believed that this persistence could be promoted in part by 
the presence of DI particles as well as the lack of development of certain aspects of the cell-
mediated immune response. However, the exact component of cell-mediated immunity has not 
been identified [16].   
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 The pathogenesis of CRS varies widely, from no apparent defects to multiple systems 
damage, and the central mechanisms are only poorly understood.  Two common features 
however, are reduced size of affected tissues, presumably due to reduced cell numbers, and 
angiopathy of early placental and embryonic tissues that interferes with fetal blood supply. The 
affects of these two pathways are manifested in various ways in the fetus. One of the most 
affected organs is the eye. Here, cellular death by necrosis and apoptosis both seem to play roles 
in either the prevention of lens development or the damage of tissue already established which 
leads to the generation of cataracts [3, 16]. When Norman Gregg was making his observations of 
fetal cataracts tied to rubella in 1941, he also noticed that these cataracts affected all but the very 
outermost layers of the lens of the eye. This would suggest that the formation of these cataracts 
began very early  in the development of the eye [10]. These assumptions were confirmed through 
experimentation with and observation of necrosis in lens fibres obtained from neonates dying 3 
weeks to 6 months after birth due to CRS related complications [16]. 
While the pathogenesis of CRS is not understood, it is very clear that the time of 
infection with regards to the stage of pregnancy is extremely important with regards to CRS 
developing in the fetus. In an experiment to determine the correlation between stage of 
pregnancy and severity of CRS, pregnant women who had been exposed to RUBV allowed their 
babies to be tested for RUBV infection, either through the detection of RUBV-specific IgM 
immediately after birth or the detection of persistent IgG after the first year of life, two common 
means of diagnosing CRS. Of these, 81% of the infants exposed during the first trimester tested 
positive for these antibodies. For mothers exposed during the second trimester, infection in 
infants dropped to 67% and in the third trimester infection was only seen in 35% [18]. The 
reasons for this correlation between pregnancy stage and the ability of the virus to cross the 
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 placenta are still unknown. However, it is possible that developmental changes in the placenta 
itself could lend to the increased defense against fetal RUBV infection in later stages of 
gestation. 
 Toward understanding the pathogenesis of CRS, two areas of experimentation have been 
pursued, namely the interference of RUBV with growth and division of infected cells [19, 20] 
and the improper induction of apoptosis in infected cells [21]. A number of studies have 
investigated the cellular effects of a persistent RUBV infection in tissue culture, a persistence 
that can be correlated to persistent fetal infection by RUBV.  RUBV persistence is maintained 
without a proviral DNA intermediate, as is seen in viral latency infections, even in the presence 
of neutralizing antibodies in the culture medium, which also correlates with persistence in the 
infected fetus from late in gestation when the fetus develops the ability to make antibodies 
through birth [19, 20, 69-74]. The mechanism by which RUBV maintains these persistent 
infections remains unclear, with hypotheses including possible roles of interferons and a more 
promising suspicion of the role of DI particles, virus mutants which interfere with virus 
replication and attenuate pathogenicity, in the establishment and maintenance of these persistent 
infections [19, 20]. However, it is evident that these infections do exert negative consequences 
against the growth of the cell culture. Most apparent are the results reported by Yoneda’s group 
in 1986 in Japan [22]. It was established that human embryonic mesenchymal cells derived from 
the palate (HEMP cells) exhibit a high sensitivity to epidermal growth factor (EGF) that results 
in high levels of collagen production and cell growth. However, once these cells are infected 
with RUBV and a persistent infection is established (HEMP-RV), the cells lose their sensitivity 
to EGF. Regardless of the levels of EGF applied, HEMP-RV cells remain unresponsive to EGF. 
It was also noted that this insensitivity was due to physiological changes in the cells which 
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 inhibited differentiation resulting in their inability to internalize EGF once it was bound to 
surface receptors or to respond to EGF-triggered signaling stimuli [22]. Thus, cells persistently 
infected with RUBV were found to have growth inhibition most likely as a result of deregulation 
in cell signaling pathways. Given that this cell line is a diploid derivative of an embryonic line, it 
can be inferred that these differentiation and growth inhibition phenomena triggered by persistent 
RUBV infection could correlate to the decrease in tissue size and development seen in fetuses 
infected with RUBV. Correlating to these findings, it was also shown that post-infection with 
RUBV certain fibroblast cell lines may actually secrete growth inhibitors into the population 
[23].  
While Vero cells infected with RUBV can produce high titers of virus and can exhibit 
cytopathic effect (the basis of plaque formation), they have also been shown to be able to 
establish persistent RUBV infection [19]. Following infection, there a 20-30% decrease in cell 
survival between 24 and 48 hrs post infection can be observed, the time period where the RUBV-
induced cytopathic effect was first observed [14].  Cytopathic effect was shown to be due to the 
induction of apoptosis in Vero cells. It was determined that apoptosis was the cause of cell death 
after it was found that these cells exhibited such apoptotic hallmarks as chromatin fragmentation 
and production of a DNA ladder upon gel electrophoresis, the binding of Annexin-V following 
disruption of the cell membrane, and inhibition of progression through the cell cycle [21].  
Nevertheless, some cells have been observed to survive and to grow into a persistently infected 
culture.  However, even during persistent infection, cytopathic effects can be observed. Under 
optimal growth conditions following subculturing, the monolayer of persistently infected cells 
remained subconfluent, while 40%-50% of cells detached and died [21].  Eventually, with 
passage of the culture, CPE was less profound which may be due to selection of attenuated virus 
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 mutants and DI RNAs. Significantly, persistently infected Vero cells cannot be cured by 
inclusion of neutralizing anti-rubella antiserum in the medium, which correlates with the 
inability of antibodies to eliminate persistence in an infected fetus before birth [20]. An 
interesting correlation to this could be achieved if similar results were obtained after adding C1 
component of complement or lymphocytes were added to the media as these are also primary 
host defenses to RUBV infection. 
RUBV-induced apoptosis has been studied in a number of cell cultures, most extensively 
in Vero, BHK21 and RK13 cells with a generalized conclusion that while RUBV definitely 
induces apoptosis [21, 80] it does so through different mechanisms and to different levels in 
different cell lines. For example, in 1999, Megyeri observed that p53, a pro-apoptotic tumor 
suppressor host protein associated with repairing extensive DNA damage, expression is elevated 
in Vero cells during infection with RUBV and that dominant-negative p53 mutants transfected 
into Vero cells during infection decreased the level of apoptosis and thus concluded that RUBV 
induces apoptosis through a p53-dependent mechanism [81]. However, in the same year 
Hofmann determined that rubella induces apoptosis through p53-independent pathways in Vero 
cells and this conclusion has been supported by Domegan’s 2002 study in rat neuronal cells 
[80,79]. The apoptosis pathways activated by RUBV are not the only aspects in dispute. While 
levels of cytotoxicity in Vero cell have been mapped to the RUBV non-structural proteins [35] 
and this thesis confirms this finding in Vero cells, C was found to induce apoptosis in RK13 cells 
as long as it contains the C-terminal 23 amino acid sequence which anchors it in the membrane 
[78]. Finally, Duncan et al [77] showed that while RUBV induces apoptosis in Vero, BHK-21, 
and RK13 cells it does so to varying levels with RK13 cells showing the most robust apoptotic 
response and BHK-21 showing the lowest levels of apoptosis induction. 
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RUBELLA, THE VIRUS   
RUBV is the sole member of the Rubivirus genus within the Togaviridae family. Other 
well-known viruses in this family include mosquito-borne Semliki Forrest Virus and Sindbis 
Virus which belong to the Alphavirus genus. RUBV is an enveloped, single-stranded, positive-
sense RNA virus with a spherical morphology ranging in diameter from 70-80 nm (Fig. 1). 
Beneath the lipoprotein envelope is an electron-dense spherical core ranging from 30-35 nm in 
diameter. Within this core resides the RUBV genome. The core, or capsid, is formed by multiple 
copies of the viral capsid protein [24] which is nonglycosylated and associates with the viral 
RNA. Projecting from the envelope are spikes, composed of the virus glycoproteins, E1 and E2 
that exhibit hemagglutination activity and are the moieties which make initial contact with the 
cell to be infected and against which neutralizing antibodies interact. While RUBV is categorized 
within the Togaviridae family, it is serologically distinct from the rest of the members of this 
family, justifying its classification as the only member of the Rubivirus genus. The multiplication 
of this virus family is highlighted by reliance on a subgenomic RNA for the translation of the 
structural proteins (Fig. 2). Initially after infection, the virion RNA, which is capped and 
polyadenylated, serves directly as the mRNA for translation of two nonstructural proteins, P150 
and P90, the genes for which lie in the 5’ two-thirds of the genome. The nonstructural proteins, 
which are replicase proteins, then copy the virion RNA into a negative-strand RNA.  It is from 
this negative-strand RNA that both positive-strand RNAs, the genomic and subgenomic RNA, 
are templated.  The subgenomic RNA, consisting of sequences from the 3’ end of the genomic 
RNA, is translated to produce the virion structural proteins, C, E2, and E1 [13]. 
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 RUBV STRUCTURAL PROTEINS 
As can be seen in Figure 2, RUBV codes for its structural proteins using the 3’ ORF. This 
ORF is accessed using a subgenomic RNA which is initiated on the negative-sense copy of the 
genome using an internal promoter. This ORF is translated into a C-E2-E1 polyprotein that is co-
translationally cleaved into its components. The RUBV capsid protein (C) has been shown to be 
a dynamic, multi-functional protein. On SDS-Page, C migrates as a doublet with its lower band 
consistently being the more intense of the two bands. It is believed that this phenomenon is due 
to the differential phosphorylation events that occur on the capsid [13]. Its migration indicates its 
molecular weight to be approximately 33kDa and the protein contains 300 amino acids. In the 
nucleocapsid, C exists as a nonglycosylated, phosphorylated homodimer linked by disulfide 
bridges. Its amino terminal half, which contains a large number of arginine residues, is extremely 
hydrophilic. Due to the overall positive charge lent by the arginines in this domain, it is believed 
that this half of the protein is responsible for binding the genomic RNA.  A specific 29-
nucleotide sequence in the genome RNA [25] has been identified as a packaging signal which 
initiates capsid formation. The carboxy-terminal 23 residues of C are highly hydrophobic, and 
they are the signal sequence for translation of the E2 glycoprotein as a membrane protein into the 
lumen of the ER. This stretch remains attached to C following cleavage by cell signalase and 
appears to be responsible for anchoring of C in cell membranes during replication.  In addition to 
forming the capsid within the virion, C’s activities include binding to the genomic RNA and 
regulating the processes of RNA replication and virion assembly, apparently through differential 
phosphorylation [25], modulation of genomic and subgenomic RNA synthesis [26], as well as 
interactions with mitochondrial proteins such as p32 that may cause the perinuclear clustering of 
mitochondria observed in infected cells [27, 28]. The capsid protein has also been shown to 
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 interact with the P150 nonstructural replicase protein, although how this binding plays a role in 
any of these functions has not been elucidated [29].  Finally, the C protein has been shown to 
induce apoptosis in RK13 cells [78]. 
Not much more is known about RUBV’ other structural proteins, E1 and E2, than is 
known about C. As can be seen in Figure 2, E2 and E1 are located downstream of capsid in the 
structural ORF with E1 being at the very end of the coding sequence. The E1 gene codes for 481 
amino acids while the E2 genes codes for 282 amino acids. During SDS polyacrylamide 
electrophoresis, E1 migrates as a distinct band at 59kDa while E2 migrates as a smear from 44-
50kDa. Since all regions of this smear yielded identical amino acid sequences, it is believed that 
this smear results from differential glycosylation of the E2 protein that result in different 
apparent molecular weights [13]. Both of these proteins contain disulfide bonds integral to their 
structure as well as N-glycosylation sites. Interestingly, changes in the N-glycosylation sites have 
been found in attenuated viruses versus their wild type counterparts, and it could be possible that 
glycosylation plays a pivotal role in vaccine attenuation [13].  In addition to N-glycosylation, E2 
also contains O-linked glycosylation.  Finally, both proteins have single predicted 
transmembrane sequences near their carboxy termini [13]. 
Thus far, only theories can be proposed for the definite mechanisms of action of these 
two proteins. It is well known that they form the spikes on the outside of the virion’s envelope, 
and it appears that E1 forms a homodimer with itself as well as a heterodimer with E2 in the 
spikes given that it is possible to immunoprecipitate both of these moieties with E1-specific 
antibodies. It appears that E1 is primarily exposed on the virion surface until it is subjected to 
low pH, at which point E2 becomes the primarily exposed protein. The functions of E1 include 
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 hemagglutinin (indicative of binding to cell receptors) and membrane fusion following exposure 
to low pH.  Most neutralizing epitopes also reside on E1 [13].  
 
RUBV NONSTRUCTURAL PROTEINS 
The RUBV non-structural proteins carry out the functions required for replication of the 
viral genome, and they are encoded and translated from the 5’ proximal open reading frame. This 
ORF codes for a P200 polyprotein that is later cleaved into the two nonstructural replicase 
proteins, P150 and P90 [13]. Not much information has been gathered with regards to the 
structures of these proteins, and it has proven challenging to isolate their functions since RUBV 
does not produce a large amount of these proteins and does not shut down host protein synthesis; 
in fact, host proteins are frequently found aiding the replication of the virus. This was first 
demonstrated by the inhibition of viral replication following the addiction of actinomycin-D (an 
inhibitor of DNA-dependent RNA polymerase activity) [83]. In addition, the termini of the 
RUBV genome are capable of forming stable stem-loop structures that have been demonstrated 
to bind go host cellular proteins such as calreticulin [84, 85]. 
Helicase and RNA-dependent-RNA polymerase (RDRP) activities reside within the P90 
replicase protein. Within the RDRP domain, a GDD motif was located that is critical to its 
function. Mutating any of these amino acids, to an alanine for example, results in the loss of 
replication of the genomic RNA [30]. In addition to its replication activities, P90 has been found 
to interact with host Citron-K kinase (CK). CK has been associated with interruptions in the cell 
cycle resulting in cells stalling just after S phase and it has been proposed that this stall results in 
tetraploidy, leading to subsequent degradation of cells and tissue, which could be a cause of 
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 RUBV’ teratogenic affects [31]. However, P90 lacks the putative binding domain for CK, and 
thus their colocalization might not be indicative of interaction. 
The P150 protein contains a methyltransferase/guanylyltransferase domain used for 
capping the genomic and subgenomic RNA as well as a cysteine protease domain with a 
catalytic site consisting of  Cys-1151 and His-1272 which performs cleavage of the P200 
precursor at Gly-1300-Gly1301 [32]. This protease activity is contingent on the protein attaining 
its proper three-dimensional shape, and this shape is considered dependent upon the binding of 
cations to the protein [33]. The function of P150 is highly susceptible to mutations anywhere in 
the N-terminus with the exception of nucleotides 1685-2192 [34]. This region, labeled NotI and 
composing 5% of the genome, seems to be dispensable, as was shown by its ability to still 
replicate the genome in the presence of a helper virus [34]. This finding was later found to be 
due to the interaction between P150 and C as C has the ability to “rescue” this deletion that is 
lethal in its absence [26]. After synthesis, P150 first associates with small vacuolar structures 
approximately 24 hours post infection and then later, at 48 hpi, moves to associate, along with 
the capsid protein, in long filamentous structures that co-localize with the cellular tubulin 
network [29]. Interestingly, determinants of cytopathogenicity in cell culture and 
arithritogenicity in synovial explants were mapped to the P150 gene [35].  
 
RUBELLA-VIRUS REPLICATION CYCLE 
Despite the fact that the sole host for RUBV is humans, a number of permissive cell lines 
from several species, both primary and continuous, have been used for scientific study. However, 
in most of these cell lines, RUBV only produces low titers and induces little to no cytopathic 
effect (CPE). RUBV grows well in two particular epithelial cell lines: BHK-21 (hamster kidney) 
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 and Vero (African green monkey kidney). These cell lines probably produce such high titers of 
the virus because both lack a functional interferon system [36], and thus the cells lack an 
intrinsic defense system against viruses. The lack of an interferon system alone, however, is not 
completely what allows these cell lines to accommodate RUBV as the virus is also able to 
establish persistent infections in cell lines with active interferon systems [36].  RUBV infection 
has also been studied in RK13 (interferon competent rabbit kidney cells) in which a dramatic 
CPE is induced, but virus titers produced are lower than in BHK or Vero cells. Even in the most 
permissive cell lines RUBV replication is extremely slow when compared to other RNA viruses, 
with a 12 hour eclipse period and production of peak titers at 36 to 48 hours post-infection [37]. 
The CPE observed as a result of RUBV infection usually appears between 36 and 48 hours post-
infection as well and consists of an increased refractive index, cell rounding and detachment, and 
debris adhering to the monolayer [13].  
 In the 1970’s multiple groups found that attachment of RUBV to host cells is fairly rapid 
compared to other RNA viruses with adhesion occurring anywhere from 30 minutes to 3 hours 
post-infection [13]. Despite the number of cell lines that RUBV can infect, its primary cellular 
receptor has not yet been elucidated. It is typical of most enveloped mammalian viruses to 
undergo receptor-mediated endocytosis after attachment (Fig. 3). Once endocytosis has occurred, 
the endosomal pH is rapidly lowered.  This results in a conformational change in the viral 
glycoproteins to allow fusion of the virus and endosomal membranes and subsequent release of 
the viral genetic material into the cytoplasm. This pathway of steps has been demonstrated 
experimentally for RUBV infection [38]. Also, it has been shown that exposing RUBV to low 
pH does induce membrane fusion activity with a concomitant conformational change in its 
glycoproteins [39], supporting the theory that this is, in fact, the pathway by which the virus 
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 enters the cell. The RUBV C protein also undergoes conformational changes under low pH that 
could expose its hydrophobic COOH region that then binds to the membrane of the endosome, 
possibly assisting in dissociation of the capsid following entry. Finally, Lee’s group showed with 
thin-section transmission electron microscopy that RUBV appears to enter cells via endocytic 
mechanisms [40]. 
 Once the RUBV genetic material has been released into the cytoplasm, replication of the 
genome begins. Because the genome is capped and polyadenylated, it is recognized by the cell as 
a messenger RNA, and thus translation starts immediately to produce the P200 polyprotein that 
is encoded by the 5’ proximal ORF. Unlike many animal viruses, RUBV does not shut down 
host protein synthesis, either at this point in the replication cycle or later. Interestingly, the AUG 
that signals where translation starts is not the AUG that is closest to the 5’ end, but rather is 37 
nucleotides downstream from the first AUG in the genomic sequence at nt 3. In fact, translation 
from an AUG this close to the 5’ end of a mRNA tends to be highly inefficient and translation of 
a functional protein from this AUG would be precluded by presence of downstream in-frame 
stop codons [13]. This AUG was also successfully removed without affecting virus replication to 
any detectable extent [41]. Once the polyprotein is made, its embedded protease self-cleaves it 
into the two non-structural proteins, P150 (at the amino terminus of the precursor) and P90 (at 
the carboxyl terminus).  
After cleavage of the P200 precursor, P150 and P90 function as a complex to transcribe a 
full-length negative-sense RNA using the genome as its template (the catalytic RDRP resides in 
P90). Two positive-sense RNA species are produced from this negative-sense transcript: a copy 
of the entire genome that is later packaged into mature virus particles as well as a “subgenomic” 
piece containing sequences from the 3’ end of the genomic RNA, including the 3’ proximal ORF 
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 encoding RUBV’ structural proteins. The subgenomic RNA is capped and polyadenylated and 
can be directly translated to produce the structural proteins [13]. 
Once the subgenomic RNA has been produced, it is used to translate the 3’ structural 
ORF into a P110 polyprotein precursor whose gene order is NH2-C-E2-E1-COOH [42]. The 
glycoprotein components of this polyprotein are translocated to the lumen of the ER by two 
distinct signal sequences that are upstream from the amino termini of E2 and E1. As translation 
occurs, ER P110 is cleaved by a cellular protease in the lumen of the ER to produce C, E2, and 
E1, and thus the P110 species is never observed in infected cells [43]. A unique characteristic of 
RUBV is the retention of the E2 signal peptide on the carboxy terminus of C and the E1 signal 
on E2. In particular, the E2 signal retained by C allows association of C with membranes [44]. 
Following the cleavage of P110 into the individual structural proteins, E1 and E2 form a 
heterodimer linked by disulfide bridges and hydrophobic interactions at the same time that C 
forms homodimers linked by disulfide bridges [45]. Upon the completion of dimer formation E2-
E1 move through the ER into the Golgi [13]. Unlike alphaviruses, which use only the plasma 
membrane as a site of maturation [46], rubella virion maturation takes place in the Golgi, rough 
ER, and cytoplasmic vacuoles [47, 48].  
The exact process of virion assembly is thus far unknown. However, it is well established 
that virus RNA replication takes place in “replication complexes”, vacuoles which seem to form 
under the surface of viral-modified endosomes and lysosomes.  The converted organelles, known 
as “cytopathic vacuoles”, recruit other cellular structures such as the RER, Golgi, and 
mitochondria to the site of replication, thus providing the replication complexes with all the 
energy, ribosomes, and protein processing required for successful, rapid replication [40, 49, 50, 
51]. These complexes allow the viral RNA to be replicated within the membrane-bound vacuoles 
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 with subgenomic RNA immediately translated by the RER and genomic RNA handed off to be 
packaged by C in association with the Golgi [3]. Once the viral RNA is packaged inside the 
capsid, the virion buds through the Golgi membrane containing E1 and E2 and into the lumen of 
the Golgi.  Virions are eventually released from the cell via exocytic pathways. 
 
 
APOPTOSIS- Programmed Cell Death 
All mammalian cells have a finite lifespan, and the mechanisms employed to execute this 
are apoptosis and autophagy. While cells also die through means of necrosis, it is advantageous 
to employ apoptosis and autophagy as mechanisms of cell death for maintenance purposes due to 
the lack of immune and inflammatory responses induced by these mechanisms of cell death as 
opposed to the extensive inflammatory and immune responses induced by necrosis. Apoptosis, or 
programmed cell death, was first discovered by Carl Vogt in 1842 and was confirmed by 
Walther Flemming 40 years later. Highly controlled and regulated, apoptosis is signaled by such 
factors as developmental programs, cell damage, viral infection, environmental stress such as 
starvation, and as a preventative against cancer. Signals for initiating apoptosis can come either 
from within the cell itself or from external environmental stimuli. In the case of cell damage and 
viral infection, the signal for apoptosis is the cell’s altruistic attempt to eliminate itself as a 
source of nutrient deprivation or viral production that could strain the organism itself without 
inducing inflammation pathways such as necrosis would. Primarily, however, apoptosis is the 
process through which cell numbers in an adult organism are kept relatively constant [52]. 
Apoptosis is highly regulated, and it is characterized by very specific morphological and 
biochemical changes within the cell. Common morphological features are cell shrinkage, 
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 chromatin fragmentation, one of the first steps in apoptosis, inversion and blebbing of the plasma 
membrane, and the eventual fragmentation of the cell into what are known as apoptotic bodies. 
These apoptotic bodies are then consumed by neighboring cells [53]. The biochemical hallmarks 
of apoptosis are chromatin fragmentation, loss of mitochondrial membrane integrity, and 
overproduction of regulatory proteins involved in the stimulation and termination of apoptosis. 
Regulation of apoptosis is pivotal to tissue health as well as development and thus must 
be highly specific. There are two main pathways which can signal the induction of apoptosis: 
intrinsic and extrinsic [54, 55]. The intrinsic pathway is initiated either by internal developmental 
signals or severe cell stress such as extreme DNA damage, a defective cell cycle, detachment 
from the extracellular matrix, hypoxia, or loss of cell survival factors. The beginning of this 
pathway is marked by the release of cytrochrome C as well as other pro-apoptotic proteins from 
the mitochondria [54, 56]. In contrast, the extrinsic pathway is initiated through the binding of a 
pro-apoptotic ligand, such as FAS ligand, to its pro-apoptotic receptor, such as FAS, which then 
undergoes a conformational change that recruits FADD and begins a signal cascade. The 
intrinsic and extrinsic pathways overlap in that both lead to the activation of cellular caspases 
[56, 57]. Caspases are the master regulators of apoptosis, and they are cysteine proteases that, 
once activated through the caspase signaling cascade, destroy cellular proteins that are critical to 
cell survival. There are two tiers of caspase activation during apoptosis: initiator caspases, 
consisting of caspases 2, 8, 9 and 10, are activated by pro-apoptotic ligand binding and cell stress 
and they in turn activate effector caspases, consisting of caspases 3, 6, and 7, which carry out 
apoptosis in a gradually expanding cascade [56, 57].  
Apoptosis is a pivotal event during the development of mammals, frequently considered 
as pivotal as cell proliferation. It aids in regulation of cell numbers and remodeling tissues and 
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 organs in the developing fetus [15]. This process of development through apoptosis has been 
compared to an artist creating a sculpture by the gradual removal of stone [58]. The development 
of tissues through the removal of cells is evidenced in the formation of ducts, tubes, digits, the 
fusion of palatal shelves, and the closure of the neuronal tube through the systematic removal of 
superfluous tissues [59-61]. Without this process, for example, humans would have webbed 
fingers and toes. It is also thought that without this process the establishment of the peripheral 
nervous system would never proceed [58]. However, despite these positive effects of apoptosis 
during fetal development, the excessive induction of apoptosis has been shown to cause 
abnormalities and birth defects [62]. It has been shown that excessive cell death consistently 
occurs in fetuses preceding the appearance of structural anomalies. In fact, studies have shown 
that known teratogenic environments such as hypo- or hyperthermia, ionizing radiation, and 
alkylating agents in the mother induce apoptosis in target fetal organs resulting in repercussions 
in correlating organs such as exencephaly, microcephalyy, and microphthalmia [62]. 
As discussed above, in the cell lines in which RUBV induces cytopathic effect, it is due 
to induction of apoptosis.   
 
 
RUBELLA VIRUS REPLICONS  
Given the relative instability of RNA species, it has become invaluable in the study of 
RNA viruses to use reverse transcriptase to construct DNA copies (cDNA) of viral RNA 
genomes. Such cDNAs can be incorporated into plasmids for amplification and mutagenesis.  If 
the cDNA is placed in a plasmid with an RNA promoter upstream of it and a unique restriction 
enzyme site downstream, in vitro transcripts of the cDNA are readily synthesized.  Because the 
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 RUBV genomic RNA is of positive polarity, the in vitro transcript initiates infection following 
transfection into susceptible cells and infectious virus results.  Alternatively, the structural 
protein ORF can be replaced with a reporter gene, such as GFP, a contruct known as a replicon 
(Fig 4).  A replicon replicates following transfection, but cannot spread from cell to cell because 
it lacks the virion proteins.    
In a recent study in our laboratory, bicistronic replicons were constructed that express a 
neomycin resistance drug-selectable marker and either GFP alone or a fusion between C and 
GFP (Fig. 4).  Following transfection of Vero cells with these replicons, drug selection was 
applied to generate a cell population uniformly harboring the replicon.  The cell lines containing 
the GFP replicon were termed IN-IN cells, and the cell line containing the C-GFP replicon were 
termed 925-IN cells [63]. Following initial drug selection, survival of 925-IN cells was roughly 
one hundred times greater than survival of IN-IN cells.  Subsequent analysis of growth of these 
cells showed that IN-IN cells grew more slowly than Vero cells and exhibited indications of 
induction of apoptosis. In contrast, the 925-IN cells grew similarly to Vero cells and lacked the 
hallmark signs of apoptosis. The C protein’s role in this striking difference in growth and 
survival is not yet understood.  The initial belief was that C, which is known to be involved in 
viral RNA replication, mediated enhanced RNA synthesis and the concomitant production of the 
drug resistance factor.  However, there was no difference between the cell lines in the amount of 
the subgenomic RNA synthesized from which the drug resistance factor would be translated, and 
Western blot confirmed that the amount of drug resistance factor was equal. The alternative 
hypothesis, based on previous observations that determinants of cytopathogenicity reside in the 
P150 gene, analyzed in this thesis is that expression of P150, alone and in the IN-IN and 925-IN 
replicons, is detrimental to cell growth and its binding to the capsid protein blocks this 
21 
 
 detrimental effect.  As discussed above, Vero cells are a nonhuman cell line that lacks a 
functional interferon system. In order to extend observations made in Vero cells to clinical 
relevance, human cell lines were analyzed for apoptosis induction in response to P150 in order to 
determine the role played by the lack of an interferon system in Vero cells with the hypothesis 
that these cells would undergo the same levels of apoptosis observed in Vero cells. 
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 GOAL OF THESIS RESEARCH 
1.  The hypothesis that the decreased survival of IN-IN cells in comparison to Vero and 
925-IN cells is due to the induction of apoptosis was tested in two ways. First, selective cell 
staining and fluorescent microscopy were used to measure caspase activation and chromatin 
fragmentation as indicators of apoptosis. Second, cells were screened using propidium iodide 
staining and flow cytometry to detect apoptosis as well as cell cycle perturbations.  
2.  The hypothesis that P150 specifically is responsible for the induction of apoptosis 
observed in IN-IN cells was examined by transfecting Vero cells with a plasmid expressing P150 
tagged with green fluorescence protein (GFP) and utilizing the methods described above to 
analyze these cells for apoptosis. To test the hypothesis that the C protein can attenuate the 
cytopathogenicity of P150, a Vero line that was generated to constitutively express the full 
length rubella capsid protein was also transfected with the P150-GFP expression plasmid and 
was also analyzed for apoptosis using the methods described above.  
 3.  Vero cells are an interferon-deficient line of African green monkey kidney cells.  To 
determine if the findings in Vero cells are relevant to human cells, and concomitantly the 
pathogenesis of CRS, two human cells lines, A549 and HEK293 cells, were transfected with the 
IN-IN and 925-IN replicons with the intent to assay for apoptosis. The cytopathogenicity of P150 
was also assayed by transfection with the P150-GFP expression plasmid and the methods to 
assay for apoptosis described previously were used.  
. 
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Figure 1: Schematic diagram of RUBV particle and genome. A: Diagram of RUBV genome. 
B: Electron micrograph of RUBV particles. C: Schematic drawing representing the structural 
arrangement of rubella’s glycoproteins, envelope, nucleocapsid, and genomic RNA.
  
 
 
 
Figure 2:  Schematic diagram of Rubella genome and replication scheme.  The large boxes 
are schematic representations of the RUBV genomic and subgenomic RNA’s with open reading 
frames denoted by boxes and untranslated regions by lines.  The separate genes with the ORF’s 
are separated by vertical lines. Thinner boxes are indicative of protein products produced. M: 
methyltransferase domain, X: function to be determined, P: protease domain, H: Helicase 
domain, R: replicase domain are motifs within the P150 and P90 replicase proteins. 
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Figure 3: Schematic of Rubella replication cycle. Artistic interpretation of the steps involved 
in RUBV replication. Referenced from Lee and Bowden 2000. 
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Figure 4: RUBV genome and replicons. Schematic of Robo502 RUBV infectious cDNA clone, 
RUBrep/GFP monocistronic replicon, IN-IN, and 925-IN bicistronic replicons.   
     CHAPTER II 
METHODS 
Cell Culture, Virus Infection, and Apoptosis Induction 
 The Vero (African green monkey kidney epithelial) cell line, purchased from the 
American Type Culture Collection (ATCC:CCL-81), was maintained at 35°C under 5% CO2 in 
Dulbecco’s minimal essential medium (DMEM) (Invitrogen, Carlsbad, Calif.) supplemented 
with 5% fetal bovine serum (FBS) and Gentamycin (10 mg/mL). The IN-IN and 925-IN cell 
lines, stably transfected with the corresponding replicons, as well as the C-Vero cell line which 
was selected for stable expression of the RUBV C protein, all provided by Dr. Wen-Pin Tzeng, 
were similarly maintained with the exception that the medium contained G418 Sulfate 
(Geneticin) antibiotic at a concentration of 100 µg/mL (Mediatech). Cells transfected with the 
IN-IP and 925-IP replicons were likewise maintained with the exceptions that the medium was 
supplemented with 10%FBS and contained Puromycin (10 ng/mL). The human cell lines 
HEK293 (human embryonic kidney transformed with adenovirus 5; provided by Dr Deborah 
Baro) and A549 (human adult lung carcinoma; ATCC:CCL-185) were maintained at 37°C under 
5% CO2 in DMEM supplemented with 10% FBS, 50 µg/mL gentamycin, 100 µg/mL penicillin, 
and 100 µg/mL streptomycin. All cell lines were routinely subcultured by trypsinzation.  
 
Transfection with P150 expressing plasmids. 
 Two transfection reagents were used to introduce plasmids expressing either GFP or a 
P150-GFP fusion protein. Both plasmids were created by Dr Wen-Pin Tzeng using VR1012 
(Vical, Inc., San Diego CA) as the backbone vector in which expression is controlled by the 
human cytomegalovirus immediate early promoter. Vero and HEK-293 cells were transfected 
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 using Lipofectamine-2000 (GIBCO) while A549 cells were transfected using GenePORTER 
(Genlantis) according to manufacturer’s protocol.  
80% confluent cells (maintained in the appropriate supplemented DMEM) in 60mm 
plates were washed two times with 1 mL of phosphate buffered saline (PBS) and one time with 1 
mL of Opti-MEM (Gibco/BRL). A mixture of 9 µg of plasmid and 7 µL of Lipofectamine-2000 
or GenePORTER in 500 µL of Opti-MEM was then added to the cells. For mock infection a 
mixture of either 7 µL of Lipofectamine-200 or GenePORTER in 500 µL of Opti-MEM was 
added to the cells. After incubating for 24 hrs, the transfection mixture was replaced with 2 mL 
of the appropriate supplemented DMEM. Following transfection, GFP expression was monitored 
with a Zeiss Axioplan microscope with epifluorescent capability and cells were analyzed for 
induction of apoptosis as described below. Microscopic images were captured using Axiovision 
3.1 software. 
  
  
Generation of Replicon Stable Cell Lines 
 Cells were transfected as described above with 12 µg of in vitro transcripts from the 
following plasmids (all provided by Dr. Wen-Pin Tzeng):  RUBrep-GFP-neo (IN-IN), RUBrep-
CGFP-neo (925-IN), RUBrep-GFP-puro (IN-IP), or RUBrep-CGFP-puro (925-IP).  Transfected 
cells were monitored using a Zeiss Axioplan microscope with epifluorescence capability for the 
expression of GFP (indicative of replicon replication). Once GFP was observed, cells were 
subjected to selection with the appropriate supplemented DMEM containing either 1000 µg/mL 
G418 or 100ng/mL puromycin to select for cells harboring the replicons. Once a homogenous 
29 
 
 population was developed it was maintained in appropriately supplemented media containing 
either neomycin or puromycin. 
 
Apoptosis assays:  Vero, IN-IN, and 925-IN cells were seeded at 104 cells/mL in 35 mm 
plates and analyzed for apoptosis (see below) every 24 hours through 4 days post-seeding.  Cells 
transfected with plasmids expressing GFP or P150-GFP were analyzed for apoptosis 48 or 72 hrs 
post transfection. Two positive controls were performed. Cells were infected with RUBV or 
treated with the PKC-inhibitor staurosporine. For infection with RUBV, cells were seeded in 35 
mm plates. After the cells reached confluency, 0.5 ml of phosphate buffered saline (PBS) 
containing 18µL of RUBV stock (Therien strain, obtained from Yumei Zhou) were added to 
obtain a multiplicity of infection of 1.0 pfu/cell and the culture was incubated at 35oC for 1 hour. 
Subsequently, the inoculum was replaced with 2mL of supplemented DMEM. In order to 
chemically induce apoptosis, cells were incubated for 1 hour in the presence of staurosporine 
(Trevigen, 0.1mM); analysis for apoptosis was performed immediately post-treatment.  
 
 
Apoptosis: Activation of Caspases 
Cells were stained with CaspaTag (Chemicon) 3,7-caspase fluorescent tag to test for the 
presence of caspase activity according to the manufacturer’s protocol. Cells were seeded on 
sterile glass coverslips in 35 mm plates containing 2mL of the appropriate supplemented 
DMEM. The media was removed and cells were washed with 1mL PBS. Cells were then 
incubated for one hour with CaspaTag reagent under 5% CO2. After incubation stain was 
removed and cells were counterstained with Hoechst stain in order to visualize nuclear 
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 morphology. Finally cells were washed two times with 2mL wash buffer and then were analyzed. 
Adherent cells were analyzed by fluorescence microscopy using a Zeiss Axioplan microscope 
with epifluorescence capability. Cells were also suspended by trypsinization and analyzed using 
a BD FACSCanto flow cytometer utilizing an Argon laser counting 10,000 events. Data was 
compiled and analyzed using FACSDivae Software. 
 
Apoptosis: Cell Cycle Disruptions 
 Cells grown in 35 mm plates were harvested through trypsinization and suspended in 
cold PBS. While vortexing vigorously, an equal volume of 70% ice cold ethanol was added drop 
wise and the suspension was incubated for no less than 30 min at 4°C. The ethanol was removed 
by low speed centrifugation and the cells were resuspended in cold PBS. The cells suspended in 
PBS were then incubated for 30 min with 50 µL RNase I (Epicenter 10 μg/mL) and 20 µL 
propidium iodide 1mg/mL (Sigma-Adrich) at 35°C and then analyzed by flow cytometry 
counting 10,000 events using a BD FACSCanto with FACSDiva software.  
 
TUNEL assay for Apoptotic DNA Fragmentation 
 Chemicon’s ApopTag Red TUNEL assay protocol was followed according to the 
manufacturer instructions. Cells grown on coverslips as described above were washed in PBS 
and fixed in 1% Paraformaldehyde in PBS for 10 min at room temperature and then washed 
twice again with PBS. Cells were then post-fixed in ice-cold 70% EtOH for 5 min at -20°C and 
washed with PBS. Equilibration buffer consisting of potassium cacodylate provided with the kit 
was applied for 10 sec and cells were incubated in reaction buffer containing digoxigenin-labeled 
nucleotides and terminal deoxynucleotide transferase (TdT) at 37°C for 1 hour in a humidified 
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chamber. Stop/Washer was applied for 10 min at room temperature and cells were washed with 
PBS. Rhodamine conjugated to anti-digoxigenin antibody was added and cells incubated for 30 
min at room temperature in the dark. After incubation cells were counterstained with DAPI to 
visualize nuclei and observed with a Zeiss Axioplan  microscope with epifluorescence capability. 
Cells were also trypsinized post-staining and the suspension was then analyzed by flow 
cytometry counting 10,000 events using a BD FACSCanto with FACSDiva software. 
 CHAPTER III 
RESULTS 
 
Analysis of cell cycle and apoptosis in IN-IN and 925-IN cells 
Induction of caspase-dependent apoptosis in IN-IN cells 
 In order to determine whether the attenuated growth exhibited by IN-IN cells was due to 
the induction of apoptosis, the activation of cellular caspases was assayed in Vero, IN-IN and 
925-IN cells over a time period of four days post-seeding using a substrate-specific fluorescent 
marker for activated effector caspases 3 and 7. It was found that caspases were activated in IN-
IN cells, but not in either Vero or 925-IN cells to a detectable degree. Over the growth cycle, 
Vero cells continued to grow until reaching confluency with only minimal caspase activation that 
could be attributed to natural cell number maintenance (Figure 5A: A-D). Like Vero cells, 925-
IN cells grew to confluency with only a perceived natural level of caspase activation (Figure 5A: 
E-H). However, the IN-IN cells showed multiple anomalies compared to these other two cell 
lines (Figure 5A: I-L). Firstly, IN-IN cells never reached confluency and cell numbers appeared 
to decline over the four-day growth curve. Secondly, these cells appeared to be almost double the 
size of either Vero or 925-IN cells. Finally, IN-IN cells exhibited activation of caspases in 
addition to other morphological hallmarks of apoptosis such as membrane blebbing and 
chromatin condensation within the nucleus.  When quantified, 40-60% of the cells exhibited 
caspase activation on each day of the experiment (Fig. 5B). 
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 Cell cycle disruption in IN-IN cells 
 As a second assay to detect apoptosis through the observation of a sub-G0 hump, FACS 
of propidium iodide-stained cells was used to measure DNA content in individual Vero, 925-IN 
and IN-IN cells harvested daily over a 4 day growth curve.  Vero and 925-IN cells showed an 
almost identical progression of the cell cycle (Figure 6) with the characteristic prominent peak 
representative of the G0/G1 phase of the cell cycle as well as a smaller peak of twice the 
fluorescence intensity representative of G2 and cells in between these peaks in S phase. 
Gradually, cells in S phase disappeared as the cells reached confluency with a G1/G0 peak and a 
small G2 peak remaining. IN-IN cells did not exhibit a pattern matching this norm in that the G2 
peak was much larger than the G0/G1 peak , indicating that these cells had stalled in G2 and were 
unable to proceed through the rest of the cell cycle and divide appropriately. An additional point 
of interest was that on day 1, cells with a DNA content greater than G2 phase were present, 
suggesting that some of the cells had become tetraploid and were proceeding into the cell cycle 
as tetraploids.  However, the proportion of such cells decreases on days 2 and 3 and the 
population disappeared on day 4.  No cells with a sub-G0/G1 DNA content, characteristic of 
apoptosis, were observed.  However, in a previous study we found that cells detach from the 
monolayer (“floaters”) and are lost in this assay [21]. 
 
Chromatin fragmentation in IN-IN cells 
Because the fragmentation of nuclear chromatin is one of the earliest hallmarks of apoptosis to 
manifest, a TUNEL assay was used to determine the extent to which fragmentation was 
occurring in Vero, 925-IN, and IN-IN cells. This was quantified by FACS as shown in Fig. 7. 
Once again, 925-IN cells exhibited little to no fragmentation above what was observable in 
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 normal Vero cells. IN-IN cells immediately exhibited elevated fragmentation on day 1 post-
seeding, approximately twice what was seen in 925-IN and Vero cells. This trend became even 
more pronounced by 2 days in IN-IN cells showing almost eight times as much fragmentation as 
925-IN cells, correlating with the level of caspase activation that is observable at this time point 
also. Interestingly, days three and four demonstrated a decrease in the level of chromatin 
fragmentation in IN-IN cells to a point that is only somewhat higher than what was observed on 
day 1 for these cells.  
 
Analysis of toxic effects of P150 and inhibition of toxicity in the presence of C 
 
Induction of caspase-dependent apoptosis in Vero cells 
 To test the hypothesis favored by the lab that P150 is the moiety responsible for RUBV 
apoptotic affects in Vero cells, including IN-IN cultures, Vero cells were mock-transfected or 
transfected with a plasmid expressing GFP or a P150-GFP fusion protein. By 48 hours post-
transfection, toxic effects of the P150-GFP expressing plasmid could be seen microscopically in 
Vero cells such as dramatic decreases in cell number, rounding of cells, and the appearance of 
floaters in the medium (data not shown). To determine if apoptosis was behind the observed 
toxicity, cells were then stained with a substrate-specific fluorescent marker for activated 
effector caspases 3 and 7 (CaspaTag). As shown in Fig. 8A, every cell that harbored the plasmid 
containing P150-GFP (fluorescing green) was also observed to have activated caspases, and thus 
was undergoing apoptosis while their counterparts in the GFP-plasmid transfected culture 
showed no detectable activation of caspases.  Quantitation by FACS revealed that ~80% of the 
35 
 
 P150-GFP transfected cells exhibited caspase activation vs ~10% of the GFP transfected cells 
(Fig. 8B).  
 Having proven that P150 does in fact induce apoptosis in Vero cells, the second part of 
the hypothesis needed to be tested, namely that C neutralized the toxic effects of P150 (possibly 
through its interaction with P150). In order to do this, a cell line that stably produces RUBV C 
protein that was previously established in our lab (termed C-Vero cells) was transfected with the 
P150-GFP plasmid.  At 48 hours post-transfection, C-Vero cells exhibited none of the cytopathic 
effect observed in similarly transfected Vero cells and no evidence of apoptosis was apparent by 
Caspatag staining (Figure 8A and B).  
 
Chromatin fragmentation in transfected Vero and CVero cells 
 As a second assay to establish the ability of P150 to cause the induction of apoptosis in 
Vero cells, the fragmentation of cellular DNA was investigated using a TUNEL assay. Vero cells 
transfected with the P150-GFP plasmid and stained 48 hours post-transfection exhibited marked 
DNA fragmentation (Figure 9 A and B) while mock-transfected and GFP plasmid transfected 
Vero cells showed no DNA fragmentation at all  further establishing the toxic effects of P150 in 
Vero cells. On the other hand, CVero cells transfected with P150-GFP as well as their mock-
transfected and GFP-plasmid transfected counterparts showed no fragmentation of the chromatin 
that was detectable.  
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 Effects of P150 on the cell cycle  
 The previous two assays established that P150 induces apoptosis in Vero cells 
independently of any other viral proteins. Next, the effects it may have on the cell cycle were 
determined. Contrary to the dramatic effects of the IN-IN replicon on the cell cycle, there 
appeared to be no effect at all in Vero cells transfected with P150-GFP (Figure 10C). In fact, 
comparison of these cells to mock-transfected (Fig. 10A) or GFP-transfected (Fig. 10B) cells 
showed no fundamental change in the pattern produced. When C-Vero cells were transfected 
with P150-GFP, they too showed no ill effects on the progression of the cell cycle (Figure 10F). 
In fact, these cells showed identical cell cycle patterns to mock-transfected (Fig 10D) and GFP-
transfected (Fig. 10E) C-Vero cells as well as mock-transfected and GFP-transfected Vero cells. 
Given that P150-GFP did not affect the cell cycle in Vero cells and P150-GFP induction of 
apoptosis was inhibited in C-Vero cells, it was expected that P150-GFP-transfected C-Vero cells 
would exhibit no abnormalities in their progression through the cell cycle. 
 
Introduction of Replicons into Human Cell Lines 
 Two human cell lines, HEK293 and A549, were transfected with the 925-IN and IN-IN 
replicons in order to ascertain if the lack of a functional interferon system played a critical role in 
the replication of the replicons in transfected cells. Due to an apparent natural immunity to the 
drug neomycin exhibited by these cell lines, an alternate replicon was obtained from Dr Wen-Pin 
Tzeng, 925-IP and IN-IP, in which the neomycin resistance marker was replaced with a 
puromycin resistance marker. Cells were monitored post-transfection through fluorescent 
microscopy for the presence of GFP. Approximately 24 hrs post-transfection GFP was detected 
and 10 ng/mL puromycin was added to the medium in order to select for cells harboring the 
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 replicons. Approximately one week post-transfection, GFP was more difficult to detect in the 
cultures. Two weeks post-transfection no GFP could be detected and all the cells in the culture 
died within three weeks. Because a stable line harboring either replicon could never be 
established, experiments could never be conducted in an identical manner to Vero cells. 
 
Analysis of P150 induction of apoptosis in human cells 
Caspase activation in transfected HEK293 and A549 cells 
 Although establishment of stably transfected human cells lines with the IN-IP and 925-IP 
replicons was not successful, to see if P150 induces apoptosis in either HEK293 or A549 cells, 
both were transfected with the P150-GFP-expressing plasmid and caspase activation was 
measured 48 hrs post-transfection. As shown in Fig. 10, the transfection efficiency of HEK 293 
cells was much higher than of A549 cells.  In both cell lines, number of caspase positive cells in 
GFP-transfected cells was similar to the mock-transfected control.  However, in the P150-GFP-
transfected cultures, there was a marked increase in the number of cells with activated caspases 
(Figs 10A, panels C and F), these caspase-positive cells did not overlap or correlate with cells 
that fluoresces green and actually harbors the plasmid expressing P150-GFP. Rather the caspase-
activated cells in the cell culture surrounded the successfully transfected (green) cells.  This 
observation was borne out by FACS analysis (Fig. 10B) which revealed no increase in caspase 
activation among P150-transfected cells in either cell line.  
 
Chromatin fragmentation in P150-transfected human cells 
 As a second assay to confirm the apparent lack of apoptosis induced by P150 in the 
human HEK293 and A549 cells, these cells were transfected with GFP- or  P150-GFP-plasmids 
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 and examined 48 hours post-transfection by TUNEL assay for the DNA fragmentation.  Both 
microscopically (Fig. 13A) and by FACS (Fig. 13B), in both cell lines, cells expressing GFP or 
P150-GFP and cells exhibiting chromatin fragmentation did not overlap, indicating that P150 did 
not induce chromatin fragmentation in either cell line.  Unlike the caspase activation assay, there 
was not an apparent increase in apoptotic cells in the P150-GFP-transfected cultures and thus 
that observation is unexplained.   
 
 
Effects of P150 on the cell cycle progression in human cells 
HEK293 and A549 cells were transfected with GFP or P150-GFP-plasmids were stained 48 
hours post-transfection with propidium iodide and analyzed by FACS.  FACS gating was 
adjusted so that propidium iodide staining was quantified in successfully transfected (ie; green) 
cells (Figure 12).  Compared with the control population which is quiescent in A549 cells, cells 
transfected with P150-GFP showed an increase in the number of cells in G2 while GFP 
transfected cells mirrored the control population.  Conversely, the GFP-transfected HEK cells 
showed an increase in cells in G2 compared with P150-GFP transfected  cells.  Thus, there was 
no consistent compelling alterations of the cell cycle induced by P150 in these two cell lines.   
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Figure 5: Analysis of caspase-dependent apoptosis in Vero, 925-IN and IN-IN cells A: Vero 
cells (panels A-D), 925-IN cells (panels E-H), and IN-IN cells (panels I-L) were seeded at a 
concentration of 104 cells/mL and allowed to grow for 1 (panels A, E, and I), 2 (panels B, F, and 
J), 3 (panels C, G, and K), or 4 (panels D, H, and L) days. Cells were then co-stained with 
CaspaTag caspase-3,7 fluorescent marker (red) and Hoechst (blue) and observed under a 
fluorescence microscope.  The green color is due to expression of a C-GFP fusion protein by 
925-IN cells and GFP by IN-IN cells.  In comparison with Vero and 925-IN cells, IN-IN cells 
exhibited decreased cell density, increased size, caspase induction, blebbing of the cytoplasmic 
membrane, and chromatin condensation (the latter two are indicated by arrows in Panels I and J, 
respectively.  B:The percentage of Vero, IN-IN, and 925-IN cells exhibiting caspase activation 
was quantitated by FACS.   The results are the mean of 4 independent experiments; the error bars 
represent the standard error of the mean.   
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Figure 6: Cell cycle analysis of Vero cells, 925-IN, and IN-IN cells  Vero cells (panels A, D, 
G, and J), 925-IN cells (panels B, E, H, and K), and IN-IN cells (panels C, F, I, and L) were 
seeded at a concentration of 104 cells/mL and grown for 1 (panels A, B, and C), 2 (panels D, E, 
and F), 3 (panels G, H, and I), or 4 (panels J, K, and L) days. Cells were stained with propidium 
iodide and analyzed by FACS.  Cell count on the Y-axis is plotted as a function of PI staining on 
the X-axis.  The peaks of cells in the G0/G1 and G2 stages of the cell cycle are indicated.  
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Figure 7: Chromatin fragmentation as an assay for apoptosis in Vero, 925-IN, and IN-IN 
cells. Vero cells, 925-IN cells, and IN-IN cells were seeded at a concentration of 104 cells/mL 
and grown for 1, 2 , 3, or 4 days. Fluorescent DNA end labeling (TUNEL), assayed by FACS for 
individual cells, was used to detect chromatin fragmentation.  The results are the mean of 4 
independent experiments; the error bars represent the standard error of the mean 
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Figure 8: Analysis of caspase-dependent apoptosis in Vero and CVero cells transfected with 
P150. A: Vero cells (panels A-C) and C-Vero cells (panels D-F) were mock-transfected (Panels 
A and D), transfected with a plasmid expressing GFP (Panels B and E) or a P150-GFP fusion 
protein (Panels C and F). At 2 days post-transfection, cells were co-stained with CaspaTag 
(Chemicon) activated caspase-3,7 marker (red) and Hoechst (Chemicon) DNA marker to 
delineate nuclei (blue).  B:  The percentage of GFP-positive cells in the GFP and P150-GFP-
transfected Vero and C-Vero cell cultures exhibiting caspase activation was quantitated by 
FACS.   The results are the mean of 4 independent experiments; the error bars represent the 
standard error of the mean.   
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Figure 9: Cell cycle analysis of Vero and C-Vero cells transfected with P150.    Vero cells 
(Panels A, C, and E) and C-Vero cells (Panels B, D, and F) were mock-transfected (Panels A and 
B) or transfected with plasmids expressing GFP (Panels C and D) or a P150-GFP fusion protein 
(Panels E and F). Approximately 48 hours post-transfection cells were stained with propidium 
iodide and analyzed by FACS.  Cell count on the Y-axis is plotted as a function of PI staining on 
the X-axis.  The total mock-transfected cell population is shown as a control while the GFP and 
P150-GFP-transfected populations were gated to include only GFP-positive cells.  The peaks of 
cells in the G0/G1 and G2 stages of the cell cycle are indicated.  
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Figure 10: Induction of apoptosis in Vero and CVero cells by P150 detected by TUNEL 
A:.Vero cells (panels A-C) and C-Vero cells (panels D-F) were mock-transfected (Panels A and 
D) or transfected with a plasmid expressing GFP (Panels B and E), or P150-GFP (Panels C and 
F). 48 hours post-transfection cells were stained by TUNEL assay (red) and counterstained with 
Hoechst (blue) to delineate nuclei.  B:  The percentage of GFP-positive cells in the GFP and 
P150-GFP-transfected Vero and C-Vero cell cultures exhibiting DNA fragmentation was 
quantitated by FACS.   The results are the mean of 4 independent experiments; the error bars 
represent the standard error of the mean. 
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Figure 11: Caspase Analysis of caspase-dependent apoptosis in A549 & HEK293 
transfected with P150.  A: A549 cells (panels A-C) and HEK 293 cells (panels D-F)) were 
mock-transfected (Panels A and D) or transfected with plasmids expressing GFP (Panels B and 
E) or P150-GFP (Panels C and E) Three days post-transfection cells were co-stained with 
CaspaTag to detect activated caspases (red) and Hoechst (blue) to delineate nuclei and analyzed 
by fluorescence microscopy    B:  The percentage of GFP-positive in the GFP and P150-GFP-
transfected A549 and HEK293 cell cultures exhibiting caspase activation was quantitated by 
FACS.   The results are the mean of 4 independent experiments; the error bars represent the 
standard error of the mean.  
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Figure 12: Cell cycle analysis of A549 & HEK293 transfected with P150.  A549 cells 
(Panels, B, D, and F) and HEK293 cells (Panels A, C, and E) were mock-transfected (Panels A 
and B) or transfected with GFP (C and D) or P150-GFP ( E and F) expressing plasmids. Two 
days post-transfection cells were stained with propidium iodide and analyzed by FACS.  Total 
cell populations are shown in mock-transfected cells in Panels A and B while the populations in 
C-F were gated to include only successfully transfected cells 
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Figure 13: Induction of apoptosis in A549 & HEK293 cells transfected with P150 detected 
by TUNEL A: A549 cells (panels A-C) and HEK293 cells (panels D-F) were mock-transfected 
(Panels A and D) or transfected with a plasmid expressing GFP (Panels B and E), or P150-GFP 
(Panels C and F. 48 hours post-transfection cells were stained by TUNEL assay (red) and 
counterstained with Hoechst (blue) to delineate nuclei.  B:  The percentage of GFP positive 
(successfully transfected) GFP- and P150-GFP-transfected A549 and HEK cells exhibiting 
caspase activation was quantitated by FACS. The results are the mean of 4 independent 
experiments; the error bars represent the standard error of the mean. 
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CHAPTER IV 
DISCUSSION 
Through the existence and use of vaccines against RUBV, the disease has been restricted 
in most developed countries of the world.  However, this virus continues to infect people 
annually at an unabated rate in developing countries.  How rubella is able to induce 
complications such as arthritis and encephalitis is still unknown, and is one of the reasons this 
virus warrants and needs continued study. However, arguably the most important reason to 
continue probing the inner molecular workings of RUBV is to work towards the eventual 
understanding of how exactly rubella causes CRS, and with this information possibly elucidate 
the mechanisms by which other viruses cause congenital birth defects. Each year, another infant 
is born with CRS related abnormalities such as mental retardation, deafness, and cataracts. Once 
it is known how rubella causes CRS it might be possible to develop strategies to prevent the 
spread of the virus from mother to fetus or to devise prenatal treatments that would prevent the 
virus from infecting and damaging multiple organ systems of the fetus. 
The purpose of this study was to more closely examine one proposed cause of CRS: the 
detrimental apoptotic effect of RUBV on the host cell. The hypothesis tested was that the RUBV 
non-structural replicase protein P150 induces apoptosis in the cell, both in the context of the 
transfected replicons and when expressed alone, and that the presence of the RUBV capsid 
protein neutralizes this apoptotic effect either alone or within the 925-IN replicon.   
The effects of  RUBV on the host cell were examined multiple ways, the first being the 
use of Vero cells transfected with bicistronic, drug-selectable replicons containing the RUBV 
non-structural ORF, the neomycin resistance gene, and either a GFP reporter gene (IN-IN) or a 
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 C-GFP in-frame fusion reporter gene (925-IN). The ability to establish a stable cell line 
uniformly harboring these replicons lent an almost complete homogeneity within the population 
that could not be duplicated in other experiments. These cell lines also provided the first 
evidence that C might play a regulatory role aiding in cell survival in that cells transfected with 
925-IN survived drug selection almost 10 times better than did cells transfected with IN-IN and 
the subsequent IN-IN cell line grew much slower than did 925-IN cells (in fact, the IN-IN cells 
could only be maintained by subculturing at a low dilution).  These results suggested C, the only 
gene difference between the two replicons, plays a substantial role in aiding host cell growth and 
survival. This would allow RUBV more time to replicate, assemble and bud from inside the host 
before the cell dies.  
The route through which C aids cell survival appears to be its ability to inhibit apoptosis 
in Vero cells. While 925-IN cells, which have C fused with GFP, grew normally and were not 
observed to show any indications of an abnormal level of apoptosis, within 24 hours of seeding 
the cells, IN-IN cells exhibited two of the earliest steps in apoptosis: the activation of caspases 
and chromatin condensation within the nucleus.  Additionally, 24 hours after seeding, IN-IN 
cells exhibited apparent cytoplasmic membrane blebbing and were substantially larger than 925-
IN and Vero cells. Despite the fact that there are regulatory mechanisms in the cell to halt 
improperly induced apoptosis, IN-IN cells seem unable to achieve this at a perceptibly efficient 
rate. Rather, 24 hours after the activation of caspases can be observed cells experience blebbing 
of the plasma membrane, and cell debris was observed 24 hours later.  
Because one of the first steps in apoptosis is fragmentation of the nuclear DNA, a 
TUNEL assay was also used to assess the level of DNA fragmentation that had occurred in IN-
IN cells. As was expected from the level of apoptosis previously observed through a caspase 
61 
 
 activation assay, IN-IN cells demonstrated a significant level of chromatin fragmentation that 
both Vero and 925-IN cells lacked. This fragmentation was observed as early as one day after 
cells were seeded, which correlates with the time frame at which caspase activation was 
observed, to high levels at 48 hours after seeding, the time when chromatin condensation was 
observed. Fragmentation levels remained elevated through the third day post-seeding in IN-IN 
cells, indicating the constant apoptotic pressure to which these cells were subjected. 
In addition to aiding cell survival, C also appears to play a role in cell cycle regulation 
and progression. FACS analysis of propidium iodide stained cells demonstrated that IN-IN cells 
suffered anomalies in cell cycle progression that 925-IN cells did not experience, and thus these 
anomalies are tied to the sole difference between the cell lines, the presence or lack of C.  These 
analyses were originally done to detect a sub-G0/G1 peak characteristic of apoptotic cells. 
However, such a peak was not observed.  In a previous study on apoptosis in RUBV-infected 
Vero cells [21], a sub-G0/G1 peak was not observed among adherent, infected cells but was 
observed among the “floater” populations of cells that had detached from the monolayer.  Thus, 
at this stage of apoptosis, Vero cells have already detached. Unexpectedly however, within 24 
hours of seeding, it could be seen that while Vero and 925-IN cells both showed cells 
predominantly in G0/G1 and S phases, IN-IN cells had almost no cells in either of these phases. 
Instead, the predominant proportion of the population appeared to be in G2 . In addition to 
stalling in G2, IN-IN cells also had cells with up to double the fluorescent intensity of G2 
indicating up to 8N aneuploidy as a result of an inability to divide multiple times. Interestingly, 
48 hours after seeding and throughout the end of the experiment the existence of 8N DNA 
content seemed to resolve, almost as though these cells were finally able to divide semi-
appropriately or died. This resolution did not lead to recovery of the cell cycle though. IN-IN 
62 
 
 cells continued to remain predominantly in G2 with only a few cells managing to divide and 
regain G0 phase.  It should be stated that it was assumed that these cells were stalled in G2 based 
on the lack of apparent increase in cell numbers; this would also explain the large size of these 
cells.  However, we could not completely rule out that the IN-IN cells had become functionally 
tetraploid as it has been observed that RUBV can induce tetraploidy in host cells [15, 23, 81]. 
 These observations indicated that without the presence of C, the products of the nsORF 
are capable of inducing abnormally high levels of apoptosis Vero cells, inducing apoptosis very 
efficiently and preventing these cells from growing normally or reaching confluency through 
disruption of the cell cycle. These effects could possibly be germane to the RUBV replication 
cycle in the stages surrounding virion assembly. Prior to assembly, the C protein is unbound in 
the cell, and thus can interact with the non-structural proteins in order to prevent their toxic 
effects and allow the cell to survive well enough for the virus to replicate. However, post-
assembly the C is bound as a homodimer forming the virion capsid, and thus can no longer 
interact with non-structural proteins to inhibit their induction of apoptosis in the host. Waiting 
until late in the replication cycle to induce apoptosis could be construed as a survival mechanism 
of the virus given that if the virus has time to fully assemble and buds from the Golgi, it could 
potentially then be caught up in apoptotic bodies and engulfed by neighboring cells, thus 
transferring itself to a new host without the immune system ever recognizing its presence in the 
system.  
In an earlier study done by the lab, RUBV-induced cytopathogenicity in Vero cells was 
mapped to the P150 gene [35]. In order to determine the role P150 plays in apoptosis, this gene 
was transfected into Vero cells through the use of a plasmid vector expressing P150 as a fusion 
protein with GFP. The apoptotic effects of P150 were seen microscopically in that rounded cells 
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 were observable in the transfected culture. Every cell that expressed P150-GFP also exhibited 
activated caspases and chromatin fragmentation indicating that these cells were undergoing 
apoptosis. This induction could be solely attributed to P150 and not either the transfection 
solution or GFP due to the fact that cells mock-transfected or transfected with a plasmid 
expressing GFP only did not show any indications of apoptosis, including activation of caspases, 
condensation of chromatin, or any morphological change indicative of apoptosis. With the first 
part of the hypothesis that P150 is capable of inducing apoptosis in Vero cells proven, the 
question that remained, however, was whether C could aid cell survival in the presence of such a 
strong apoptosis inducer. This question was answered by transfecting a Vero cell line that stably 
expresses C (CVero) with the plasmids containing GFP or P150-GFP. These cells showed no 
indications of apoptosis whether transfected with GFP alone or P150-GFP either 48 hours post-
transfection or one week post-transfection (data not shown). This confirms the observations 
made in experiments with replicons in that without C cells exposed to P150 undergo apoptosis 
while those with C are saved from apoptosis, proving the second part of the hypothesis.  In a 
previous study by the lab, it was shown that C and P150 associate in the cell.  While a corollary 
hypothesis is that this association is necessary for C to prevent apoptosis induced by P150, the 
experiments done in this study neither prove nor disprove this corollary hypothesis. Also beyond 
the scope of this study is the explanation as to why C is such an anti-apoptotic protein in Vero 
cells, and yet is such a pro-apoptotic protein when expressed in RK13 cells [78]. One highly 
interesting commonality between the two cell lines is the necessity for C to contain its C-
terminal 23 amino acid membrane association sequence (the E2 signal sequence) in order to 
perform either of these functions (pro- or anti-apoptotic) [78, data not shown]. One possible 
explanation for this could be that without being membrane-bound, as it is when containing this 
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 signal sequence, C undergoes moderate conformational changes that slightly alter its 
functionality. 
Interestingly, the correlating results between transfection with P150 and the IN-IN 
replicon on induction of apoptosis did not translate to effects on the cell cycle.  Both Vero and 
CVero cells transfected with P150-GFP showed a normal cell cycle progression. In fact, the only 
noticeable difference between the two cell lines transfected with P150-GFP was a slightly higher 
percentage of CVero cells in G0 phase. Obviously, P150 was not subjecting Vero cells to the 
same cell cycle arrest as the IN-IN replicon does in the stably transfected cells despite the clear 
apoptotic effects in both.  The Vero cells transfected with P150-GFP were almost confluent and 
thus normally the majority of cells in the culture would not be undergoing cell cycles subsequent 
to transfection with P150 while the IN-IN cells were lightly seeded and thus the majority would 
enter the cell cycle.  The induction of apoptosis under both conditions suggested that apoptosis 
was not a result of the stall in G2 phase.  Whether the G2 stall in IN-IN cell was the initiator of 
apoptosis or an independent mechanism was not answered within the scope of this study, but 
should still be investigated further. Interestingly, these results are consistent with a hypothesis 
advanced in another study that P90, the other replicase protein is responsible for cell cycle arrest 
[31].   It was shown that P90 colocalizes with and binds to a cytokinesis-regulatory protein, 
Citron-K kinase (CK) and hypothesized in the same study that this interaction interferes with 
CK’s normal function, and thus inhibits cells from dividing, resulting in tetraploidy [31].  Vero 
cell lines selected to constitutively express P90 were found to exhibit a G2 block 24 hours post-
seeding (albeit 24% of the cells vs almost 100% of IN-IN cells).  The association of P90 with 
induction of apoptosis was not addressed in that study, but it is assumed that it was not profound 
if stable cell lines could be established.  We have likewise been able to establish P90-stable cell 
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 Vero lines, but cannot do so with P150 because of its inherent cytotoxicity (W.P. Tzeng, 
unpublished results).  Thus P150 may induce apoptosis while P90 interferes with the cell cycle.     
As interesting as these results are, the fact that Vero cells are interferon deficient could 
not be ignored. Thus, investigation as to whether these observations translate into a human cell 
culture with an intact interferon system was pursued using adult (A549) and fetal (HEK293) 
epithelial cells. Unfortunately, despite their ability to support replication by RUBV these cells 
never accepted either the 925-IN or the IN-IN replicon for more than 72 hours, likely because the 
replicon was eliminated by the interferon system, as was found to occur when noncytopathic 
replicons were transfected into murine embryo fibroblasts with an active interferon system [82]. 
It therefore was impossible to determine whether they would suffer cell cycle arrest and 
apoptosis in the same way that Vero cells harboring these replicons did. Therefore, 
experimentation in human cells was limited to exploring the effects of P150 and whether it 
would exhibit a high level of cytotoxicity in these cells. 
When P150-GFP was transfected into both human cell lines, it had a much lower level of 
cytotoxicity, if it was at all. In fact, A549 cells that were transfected with P150 give no indication 
of suffering apoptosis related to P150-GFP. Rather, caspase activation was present in more of the 
untransfected cells than in those that were successfully transfected with P150-GFP. A similar 
result was seen when HEK293 cells were transfected with P150-GFP. While there was a higher 
number of cells with activated caspases in the culture of P150-GFP transfected cells versus mock 
transfected cells, very few of the caspase-active cells (roughly 10%) overlap with successfully 
transfected cells producing GFP. While these results indicate that P150-GFP did not activate 
caspases in the cell, we could not explain the higher number of cells with activated caspases in 
the P150-GFP-transfected culture.   
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 The lack of induction of apoptosis by P150 apparent in the caspase activation 
experiments was confirmed by the lack of chromatin fragmentation in these cell lines transfected 
with P150-GFP. A549 cells that had been transfected with GFP exhibited the same level of 
fragmentation as, if not more than, those transfected with P150-GFP indicating that P150 is no 
more toxic to these cells than either the transfection reagent itself or GFP. Likewise, P150 did 
not induce chromatin fragmentation in HEK293 cells any more than GFP did, once again 
demonstrating a lack of elevated cytotoxicity that could be attributed to P150 alone. The spurious 
induction of apoptosis in cells neighboring the P150-GFP transfected cells observed in the 
caspase activation assay was not observed using the TUNEL assay.  Because P150 gave no 
indications of inducing apoptosis in human cells, it was unnecessary to investigate whether C 
would be able to neutralize induction of apoptosis.  
FACS analysis showed that both HEK293 and A549 cells that have been transfected with 
either GFP or P150-GFP showed no indication of cell cycle arrest, similar to Vero cells 
transfected with these plasmids. Instead, P150- or GFP-transfected HEK293 cells exhibited 
normal cell cycle progression with no suggestion of arrest in G2 or an inability to divide. 
Likewise, A549 cells, whether mock transfected or transfected with GFP or P150, also exhibited 
normal cell cycle progression.  However, since these cells were near confluency at the time of 
transfection with P150-GFP, as were the Vero cells, we do not know if inhibition of the cell 
cycle would be observed if the cells were actively dividing at the time of transfection.    
The lack of apoptosis induced in human cells could be attributed to a number of factors, 
one being the presence of a functional interferon system in these cells that Vero cells lack.  
However, studies by other laboratories have shown that apoptosis in response to RUBV infection 
varies among cell lines and that BHK cells, which also lack a functional interferon system, do 
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 not exhibit RUBV induced CPE due to apoptosis [77]. A recent study investigating apoptosis 
induction by infection with RUBV in fetal and adult human cells used microchip analysis to 
investigate which genes were regulated by RUBV, and both pro- and anti-apoptotic genes were 
affected in cells infected with this virus.  In this and a previous study, the adult cells were found 
to undergo apoptosis while the fetal cells did not. Both fetal and adult cells exhibited a robust 
interferon response, lending  support to the idea that simply having an active interferon system 
within the host cell does not make a large difference in whether apoptotic pathways are triggered 
or not [66].   
The question that remains then is how exactly the RUBV P150 protein is able to induce 
apoptosis in Vero cells to such an extraordinary level. It has been established through 
experimentation with UV-inactivated RUBV that active replication is required for RUBV to 
induce apoptosis [76, 80] as well as normal cell growth and proliferation [75] lending weight to 
the hypothesis that RUBV induces apoptosis through the intrinsic pathways. The exact members 
of the pathways have not yet been definitively identified, however. While there has been some 
evidence of a p53-dependent pathway being activated [81] there is also evidence countering this 
and supporting the theory that the Akt survival pathway and Bcl-2 pathways are more pivotal 
towards RUBV’ activation of apoptosis in host cells [75, 77]. Without knowing the exact 
pathway activated, it is difficult to determine the exact mechanism employed by P150 for 
apoptosis induction, however towards answering this question multiple theories could be 
explored. The first theory that could be proposed is one of substrate confusion given that both 
caspases and P150 are cysteine proteases with His and Cys as members of their catalytic site [25, 
67]. The action of effector caspases 3, 6, and 7 is reliant on their proteolytic cleavage and 
subsequent activation by initiator caspases 8, 9, and 10. Activation of these initiator caspases is 
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 reliant upon proteolytic self-cleavage signaled by pro-apoptotic regulatory proteins. Previous 
studies with HIV-1 in Jurkat cells have demonstrated through SDS-PAGE the ability of HIV’s 
protease (PR) to cleave procaspase-8. This cleavage also did not produce the exact same subunits 
as normal cleavage of procaspase-8 would. However, immunofluorescent labeling also showed 
that once cleaved through this mechanism the caspase was able to begin its signal cascade and 
amplification resulting in the induction apoptosis in these cells [68]. One primary difference 
between the HIV protease versus caspase and P150 is that while P150 and caspases are both 
cysteine proteases, PR is an aspartyl protease. The relevance of this is that even though P150 
cleaves between two glycines while caspases cleave after an aspartic acid it could still be 
possible that P150 is able to cleave procaspase-8 in a manner similar to PR thus producing an 
active initiator caspase whose signal is amplified and induces apoptosis.  
In conclusion, the results presented in this M.S. Thesis demonstrate that while P150 is 
capable of inducing apoptosis in Vero cells and that C is able to neutralize these apoptotic 
effects, these results are cell-type specific.  Thus, if induction of apoptosis by RUBV contributes 
to CRS, it is in a cell-specific manner.  RUBV replicons were able to induce a uniform cell cycle 
arrest in Vero cells typical of RUBV infection and this system is a candidate for studying the 
mechanisms behind this arrest, which are apparently not related to induction of apoptosis. 
However, given that aneuploidy has been linked to certain types of cancer [64] and thus there are 
cellular checkpoints to monitor and eliminate cells with aneuploidy, this theory should not be 
completely discarded. It stands to reason that this aneuploidy is triggering apoptosis and this 
could be the mechanism through which RUBV induces apoptosis leading to the developmental 
abnormalities witnessed in CRS. This theory has been substantiated by experimentation using 
knockout mice defective in a pivotal cell division signaling protein. These mice lack consistent 
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 appropriate cell division and thus suffer apoptosis and developmental abnormalities [65]. Since 
G2 arrest is also a hallmark of cancer as well as polyploidy [64] it could also be possible that it is 
the combined effects of polyploidy and arrest in G2 that are sounding the anti-cancer alerts in the 
cell and instigating apoptosis.  As with the induction of apoptosis, study of interference with the 
cell cycle needs to be extended to other cell types to see if it is cell type specific or a general 
phenomenon. Most importantly these studies need to be carried out in fetal cell lines.  Thus far, 
RUBV has not been found to induce apoptosis in human fetal fibroblasts [81,66] and we found 
that P150 did not induce apoptosis in HEK 293, a fetal cell line. The variability in apoptosis 
induction depending on cell type could be a prime candidate to explain the specific types of 
damage encountered following fetal infection. It could also lend explanation as to why some 
aspects of CRS appear to be caused by apoptosis while others seem more necrotic in nature. 
Despite the inability of this study to truly identify specific molecular causes of CRS, it has shed 
light on a number of future directions that could be taken towards solving this enigmatic puzzle.  
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